CN117769443A - 成纤维细胞活化蛋白抑制剂及其用途 - Google Patents

成纤维细胞活化蛋白抑制剂及其用途 Download PDF

Info

Publication number
CN117769443A
CN117769443A CN202280050775.2A CN202280050775A CN117769443A CN 117769443 A CN117769443 A CN 117769443A CN 202280050775 A CN202280050775 A CN 202280050775A CN 117769443 A CN117769443 A CN 117769443A
Authority
CN
China
Prior art keywords
compound
tumor
specified
compounds
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280050775.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·奥斯特坎普
D·茨伯拉尔斯奇
M·帕斯切克
A·霍尼
J·瓦什纳特什内尔
C·哈瑟
U·雷奈克
C·斯梅尔灵
J·翁格维斯
A·布雷登贝克
C·基普森
J·萨柏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Publication of CN117769443A publication Critical patent/CN117769443A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280050775.2A 2021-07-23 2022-07-22 成纤维细胞活化蛋白抑制剂及其用途 Pending CN117769443A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187424.3A EP4122499A1 (en) 2021-07-23 2021-07-23 Fibroblast activation protein inhibitors and use thereof
EP21187424.3 2021-07-23
PCT/EP2022/070693 WO2023002045A1 (en) 2021-07-23 2022-07-22 Fibroblast activation protein inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CN117769443A true CN117769443A (zh) 2024-03-26

Family

ID=77042830

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050775.2A Pending CN117769443A (zh) 2021-07-23 2022-07-22 成纤维细胞活化蛋白抑制剂及其用途

Country Status (11)

Country Link
US (1) US20240335569A1 (https=)
EP (2) EP4122499A1 (https=)
JP (1) JP2024527627A (https=)
KR (1) KR20240040092A (https=)
CN (1) CN117769443A (https=)
AU (1) AU2022313521A1 (https=)
CA (1) CA3224514A1 (https=)
CL (1) CL2024000200A1 (https=)
IL (1) IL310306A (https=)
MX (1) MX2024000866A (https=)
WO (1) WO2023002045A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118978511A (zh) * 2024-08-02 2024-11-19 江苏华益科技有限公司 一种靶向fap化合物及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4342890A1 (en) * 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
WO2025106939A1 (en) * 2023-11-16 2025-05-22 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof
CN119604492A (zh) * 2023-12-08 2025-03-11 北京师范大学 一种放射性标记fapi配合物及其制备方法和应用
WO2025167951A1 (zh) * 2024-02-07 2025-08-14 苏州博锐创合医药有限公司 一种成纤维细胞活化蛋白抑制剂
WO2025240871A1 (en) * 2024-05-16 2025-11-20 Purdue Research Foundation Chemically stable keto-amide-based fibroblast activation protein-targeted nanoparticle-based magnetic resonance imaging agent, compositions, and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CN103370063A (zh) 2010-12-13 2013-10-23 免疫医疗公司 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物
DE102014115088A1 (de) 2014-10-16 2016-04-21 Sovicell Gmbh Bestimmung von Bindungskonstanten mittels Gleichgewichtsverlagerung
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118978511A (zh) * 2024-08-02 2024-11-19 江苏华益科技有限公司 一种靶向fap化合物及其制备方法
WO2026025908A1 (zh) * 2024-08-02 2026-02-05 江苏华益科技有限公司 一种靶向fap化合物及其制备方法

Also Published As

Publication number Publication date
KR20240040092A (ko) 2024-03-27
IL310306A (en) 2024-03-01
AU2022313521A1 (en) 2023-12-14
CA3224514A1 (en) 2023-01-26
EP4122499A1 (en) 2023-01-25
MX2024000866A (es) 2024-02-09
WO2023002045A1 (en) 2023-01-26
EP4373529A1 (en) 2024-05-29
AU2022313521A9 (en) 2024-01-04
CL2024000200A1 (es) 2024-06-14
US20240335569A1 (en) 2024-10-10
JP2024527627A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
CN114341159B (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN114341158B (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN117769443A (zh) 成纤维细胞活化蛋白抑制剂及其用途
CN116940585A (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN116940586A (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
WO2022123462A1 (en) Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
AU2022410422A1 (en) Carbonic anhydrase ix ligands
CN118591549A (zh) 碳酸酐酶ix配位体
US20260083865A1 (en) Prostate specific membrane antigen (psma) ligands and use thereof
RU2836270C2 (ru) Соединения, содержащие лиганд белка активации фибробластов, и их применение
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination